Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor


  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:CTRP9A, Complement C1q tumor necrosis factor-related protein 9, C1QTNF9,C1QTNF9A,UNQ6503/PRO21380
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RD191180200R 96 wells (1 kit)
PubMed Product Details
Technical Data


Sandwich ELISA, Biotin-labelled antibody


Serum, Plasma

Sample Requirements

10 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

25–800 pg/ml

Limit of Detection

9.0 pg/ml

Intra-assay (Within-Run)

n = 8; CV = 5.5%

Inter-assay (Run-to-Run)

n = 8; CV = 7.9%

Spiking Recovery


Dilution Linearity



  • bovine Non-detectable
  • cat Non-detectable
  • goat Non-detectable
  • hamster Non-detectable
  • horse Yes
  • dog Yes
  • mouse Non-detectable
  • rabbit Non-detectable
  • rat Non-detectable
  • sheep Non-detectable
  • chicken Not tested
  • monkey Yes
  • pig Yes
  • human Yes


  • It is intended for research use only
  • The total assay time is less than 4 hours
  • The kit measures CTRP9 protein in human serum and plasma (EDTA, citrate, heparin)
  • The kit measures CTRP9 protein in serum of several mammalian species such as dog, horse, monkey and pig
  • Assay format is 96 wells
  • Quality Control is human serum based. No animal sera are used
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Cardiovascular disease, Cytokines and chemokines and related molecules, Energy metabolism and body weight regulation


Complement C1q tumor necrosis factor-related protein 9 (C1q/TNF-related protein 9; CTRP9) is a highly conserved paralog of adiponectin. Of all the CTRP paralogs, CTRP9 shows the highest degree of amino acid identity to adiponectin in its globular C1q domain. CTRP9 protein exists in two isoforms, CTRP9A and CTRP9B. Although human CTRP9A and CTRP9B share 98% amino acid identity, they are encoded by distinct genes and are biochemically distinct. Human CTRP9A but not CTRP9B is expressed by adipose tissue. CTRP9B is expressed at very low levels in tissues. While CTRP9A is robustly secreted as a multimeric protein, CTRP9B requires physical association with CTRP9A or adiponectin for its secretion. CTRP9 is expressed predominantly in adipose tissue and females express higher levels of the transcript than males. Moreover, its expression levels in ob/ob mice changed in an agedependent manner, with significant up-regulation in younger mice. Adenovirus-mediated overexpression of CTRP9 in obese (ob/ob) mice significantly lowered serum glucose levels. CTRP9 is a secreted glycoprotein with multiple post-translational modifications in its collagen domain that include hydroxylated prolines and hydroxylated and glycosylated lysines. It is secreted as multimers (predominantly trimers) from transfected cells and circulates in the mouse serum with levels varying according to sex and metabolic state of mice. Furthermore, CTRP9 and adiponectin can be secreted as heterooligomers when cotransfected into mammalian cells, and in vivo, adiponectin/CTRP9 complexes can be reciprocally coimmunopreci­pitated from the serum of adiponectin and CTRP9 transgenic mice. The functional role of the plasma CTRP9 in ischemic heart disease is unknown. Systemic delivery of CTRP9 reduces myocardial infarct size and apoptosis following ischemiareperfusion in mice. CTRP9 protects cardiomyocyte from apoptosis through activation of AMPactivated protein kinase (AMPK). CTRP9 prevents acute cardiac ischemic injury via an AMPKdependent mechanism. The data indicate that CTRP9 functions to attenuate neointimal formation following vascular injury through its ability to inhibit vascular smooth muscle cell (VSMC) growth via cAMPdependent mechanism, suggesting that the therapeutic approaches to enhance CTRP9 production could be valuable for prevention of vascular restenosis after angioplasty. CTRP9 is a novel vasorelaxive adipocytokine which may exert vasculoprotective effects via the AdipoR1/AMPK/eNOS dependent/NO mediated signaling pathway. The vasoactive potency of CTRP9 exceeded that of adiponectin by 3-fold. Cardiac expression of CTRP9, exceeds adiponectin by >100-fold, and is significantly reduced in high-fat diet-induced diabetic mice. In H9c2 cells, TNF-α strongly inhibited CTRP9 expression (>60 %), and significantly reduced peroxisome proliferator activated receptorgamma (PPARγ), a known transcription factor promoting adiponectin expression.

Product References (1)


  • Appari M, Breitbart A, Brandes F, Szaroszyk M, Froese N, Korf-Klingebiel M,Mohammadi MM, Grund A, Scharf GM, Wang H, Zwadlo C, Fraccarollo D, Schrameck U,Nemer M, Wong GW, Katus HA, Wollert KC, Müller OJ, Bauersachs J, Heineke J.C1q-TNF-Related Protein-9 Promotes Cardiac Hypertrophy and Failure. Circ Res.2017 Jan 6;120(1):66-77. doi: 10.1161/CIRCRESAHA.116.309398. Epub 2016 Nov 7.PubMed PMID: 27821723. See more on PubMed
Summary References (6)

References to Complement C1q Tumor Necrosis Factor-Related Protein 9A

  • Kambara T, Ohashi K, Shibata R, Ogura Y, Maruyama S, Enomoto T, Uemura Y, Shimizu Y, Yuasa D, Matsuo K, Miyabe M, Kataoka Y, Murohara T, Ouchi N. CTRP9 protein protects against myocardial injury following ischemia-reperfusion through AMP-activated protein kinase (AMPK)-dependent mechanism. J Biol Chem. 2012 Jun 1;287 (23):18965-73
  • Peterson JM, Wei Z, Wong GW. CTRP8 and CTRP9B are novel proteins that hetero-oligomerize with C1q/TNF family members. Biochem Biophys Res Commun. 2009 Oct 16;388 (2):360-5
  • Su H, Yuan Y, Wang XM, Lau WB, Wang Y, Wang X, Gao E, Koch WJ, Ma XL. Inhibition of CTRP9, a novel and cardiac-abundantly expressed cell survival molecule, by TNFalpha-initiated oxidative signaling contributes to exacerbated cardiac injury in diabetic mice. Basic Res Cardiol. 2013 Jan;108 (1):315
  • Uemura Y, Shibata R, Ohashi K, Enomoto T, Kambara T, Yamamoto T, Ogura Y, Yuasa D, Joki Y, Matsuo K, Miyabe M, Kataoka Y, Murohara T, Ouchi N. Adipose-derived factor CTRP9 attenuates vascular smooth muscle cell proliferation and neointimal formation. FASEB J. 2013 Jan;27 (1):25-33
  • Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Ge G, Spooner E, Hug C, Gimeno R, Lodish HF. Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin. FASEB J. 2009 Jan;23 (1):241-58
  • Zheng Q, Yuan Y, Yi W, Lau WB, Wang Y, Wang X, Sun Y, Lopez BL, Christopher TA, Peterson JM, Wong GW, Yu S, Yi D, Ma XL. C1q/TNF-related proteins, a family of novel adipokines, induce vascular relaxation through the adiponectin receptor-1/AMPK/eNOS/nitric oxide signaling pathway. Arterioscler Thromb Vasc Biol. 2011 Nov;31 (11):2616-23
Related Products Docs